A Phase 1 Study of a Neoantigen Vaccine Regimen and Ipilimumab for the Treatment of MPN
Research type
Research Study
Full title
A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms
IRAS ID
1005965
Contact name
David Wright
Contact email
Sponsor organisation
Janssen-Cilag International NV
Eudract number
2021-006033-20
ISRCTN Number
ISRCTN83349329
Clinicaltrials.gov Identifier
Research summary
Myeloproliferative neoplasms (MPNs) are a group of blood cancers in which the bone marrow makes too many red/white blood cells or platelets or develops scarring that prevents the production of normal cells. MPNs are rare, and the most common types are essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). Due to limited treatment options available, new effective therapies are needed. One approach is a vaccine to train the immune system to reduce the growth of cancer cells and improve the quality of life of patients with these diseases.
VAC85135 is a combination vaccine, with two distinct forms, that uses two different viruses carrying genetic material encoding protein fragments only expressed in cancer cells. The goal of the vaccine is to train the immune system to attack the cancer cells that express these abnormal proteins.
The study is designed to see if VAC85135 can be safely administered to adult participants with MPNs in combination with ipilimumab.REC name
South Central - Oxford A Research Ethics Committee
REC reference
22/SC/0427
Date of REC Opinion
2 Feb 2023
REC opinion
Further Information Favourable Opinion